Voractiv: quadruple TB combination tablet

Voractiv (rifampicin/isoniazid/pyrazinamide/ethambutol) is a fixed-dose combination tablet containing four antibacterial agents that have antimicrobial activity against Mycobacterium tuberculosis.

Voractiv contains rifampicin 150mg, isoniazid 75mg, pyrazinamide 400mg and ethambutol 275mg
Voractiv contains rifampicin 150mg, isoniazid 75mg, pyrazinamide 400mg and ethambutol 275mg

Voractiv is licensed for the treatment of TB during the initial intensive phase, in accordance with WHO guidelines.

Rifampicin is a rifamycin antibiotic. Isoniazid, pyrazinamide and ethambutol are bactericidal antituberculous agents.

Voractiv is given once daily for 2 months, with or without concomitant streptomycin. Treatment is then continued with rifampicin/isoniazid, isoniazid/ethambutol or rifampicin/isoniazid/ethambutol.

View Voractiv drug record

Further information: Genus Pharmaceuticals

Follow MIMS on Twitter


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases